First Wave BioPharma to Participate in ”Fireside Chat” at the 34th Annual Roth Conference
March 08, 2022 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., March 08, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Announces Poster Presentation at the 2022 Digestive Disease Week (DDW) Conference
March 03, 2022 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., March 03, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma, Inc. Announces Closing of $9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
March 02, 2022 17:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., March 02, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (the “Company”), a clinical stage biopharmaceutical company specializing in the development of...
First Wave BioPharma Announces Appointment of Sarah Romano as Chief Financial Officer
March 01, 2022 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., March 01, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
InveniAI to Participate in the Truist Securities Life Sciences AI Symposium – Biotech & Tools
February 24, 2022 12:39 ET
|
InveniAI LLC
GUILFORD, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- InveniAI® LLC, a global leader in applying Artificial Intelligence (AI) and Machine Learning (ML) to transform drug discovery and development,...
Metacrine Updates IBD Clinical Development Strategy and Implements Restructuring Plan
February 11, 2022 08:05 ET
|
Metacrine, Inc.
U.S. FDA clears IND to evaluate MET642 for the treatment of ulcerative colitisSufficient capital to complete Phase 2 IBD trial SAN DIEGO, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc....
First Wave BioPharma to Participate in the 2022 BIO CEO & Investor Conference
February 07, 2022 07:30 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Feb. 07, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Announces Adjournment of Annual Meeting
December 17, 2021 09:06 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Dec. 17, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Chairman and CEO Issues Letter to Shareholders
December 13, 2021 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Dec. 13, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Names Brian Feagan, M.D., to Scientific Advisory Board
December 09, 2021 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Dec. 09, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...